Axsome Therapeutics, Inc. Quarterly Deferred Tax Assets, Gross in USD from Q4 2015 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
Axsome Therapeutics, Inc. quarterly Deferred Tax Assets, Gross history and growth rate from Q4 2015 to Q4 2023.
  • Axsome Therapeutics, Inc. Deferred Tax Assets, Gross for the quarter ending December 31, 2023 was $225M, a 22% increase year-over-year.
Deferred Tax Assets, Gross, Quarterly (USD)
Deferred Tax Assets, Gross, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $225M +$40.7M +22% Dec 31, 2023 10-K 2024-02-23
Q4 2022 $185M +$26.8M +17% Dec 31, 2022 10-K 2024-02-23
Q4 2021 $158M +$49.2M +45.3% Dec 31, 2021 10-K 2023-02-28
Q4 2020 $109M +$40.1M +58.7% Dec 31, 2020 10-K 2022-03-01
Q4 2019 $68.4M +$27.2M +65.8% Dec 31, 2019 10-K 2021-03-01
Q4 2018 $41.3M +$12.4M +43.1% Dec 31, 2018 10-K 2020-03-12
Q4 2017 $28.8M +$6.74M +30.5% Dec 31, 2017 10-K 2019-03-15
Q4 2016 $22.1M +$14.3M +185% Dec 31, 2016 10-K 2019-03-15
Q4 2015 $7.76M Dec 31, 2015 10-K 2017-03-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.